Antiphospholipid Syndrome (APS) Clinical Trials

7 recruiting

Antiphospholipid Syndrome (APS) Trials at a Glance

7 actively recruiting trials for antiphospholipid syndrome (aps) are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Madrid, Austin, and Baltimore. Lead sponsors running antiphospholipid syndrome (aps) studies include China Immunotech (Beijing) Biotechnology Co., Ltd., Chugai Pharmaceutical, and Infanta Leonor University Hospital.

Browse antiphospholipid syndrome (aps) trials by phase

Treatments under study

About Antiphospholipid Syndrome (APS) Clinical Trials

Looking for clinical trials for Antiphospholipid Syndrome (APS)? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Antiphospholipid Syndrome (APS) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Antiphospholipid Syndrome (APS) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting
Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721
Recruiting

Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients

ThrombophiliaAntiphospholipid Syndrome (APS)Venous Thrombosis (Disorder)
Infanta Leonor University Hospital600 enrolled2 locationsNCT07372170
Recruiting

Follow-up Cohort of Patients With Antiphospholipid Syndrome

Antiphospholipid Syndrome (APS)
University Hospital, Rouen200 enrolled1 locationNCT07178925
Recruiting
Phase 1

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Inflammatory Myopathy+5 more
China Immunotech (Beijing) Biotechnology Co., Ltd.12 enrolled1 locationNCT06978647
Recruiting
Phase 2

Effect of Belimumab on Antibody Titers in Primary APS Patients

Antiphospholipid Syndrome (APS)
Ruijin Hospital20 enrolled1 locationNCT06747312